10-Q: Hyperliquid Strategies Completes Merger, Secures $300M+

Hyperliquid Strategies Inc. completed its business combination with Sonnet BioTherapeutics and Rorschach, raising significant capital and listing on Nasdaq, despite initial operating losses.

Summary

• Hyperliquid Strategies Inc. (PURR) was incorporated on July 2, 2025, and completed a business combination with Sonnet BioTherapeutics Holdings, Inc. and Rorschach I LLC on December 2, 2025.
• The company reported a net loss of $1,212,921 for the period from inception (July 2, 2025) through September 30, 2025, with basic and diluted net loss per share of $13,183.92.
• As of September 30, 2025, total current liabilities were $1,212,921, primarily consisting of accounts payable and accrued expenses ($1,138,335) and amounts due to related parties ($74,586).
• The company received approximately $299,900,000 in cash and 12,500,000 HYPE tokens from investors concurrently with the closing of the Transaction, alleviating prior going concern doubts.
• Post-closing, Hyperliquid Strategies has 127,025,563 shares of Common Stock outstanding, along with Series A Preferred Stock, Advisor Warrants, and other warrants.
• The company entered into a Purchase Agreement with Chardan Capital Markets LLC on October 22, 2025, allowing it to sell up to $1,000,000,000 of Common Stock at its discretion.
• Common Stock began trading on the Nasdaq Capital Market under the symbol PURR on December 3, 2025.
• The board of directors authorized a stock repurchase program of up to $30 million of common stock for up to 12 months, announced on December 8, 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the successful completion of a significant business combination, a substantial capital infusion, and securing a large future financing facility, which addresses prior going concern issues. The Nasdaq listing and stock repurchase program also contribute positively. However, the pre-revenue status and high dependence on volatile HYPE tokens introduce considerable risk, tempering overall optimism.

Positives

• Successful completion of the business combination with Sonnet BioTherapeutics Holdings, Inc. and Rorschach I LLC on December 2, 2025, establishing the company's operational structure.
• Raised approximately $299,900,000 in cash and 12,500,000 HYPE tokens from investors, significantly improving liquidity and alleviating prior going concern doubts.
• Secured a flexible equity financing facility with Chardan Capital Markets LLC for up to $1,000,000,000, providing substantial future capital access.
• Common Stock commenced trading on the Nasdaq Capital Market under 'PURR' on December 3, 2025, enhancing market visibility and liquidity.
• Board authorized a $30 million stock repurchase program, signaling confidence in the company's valuation and potentially supporting share price.

Negatives

• Reported a net loss of $1,212,921 for the period from inception (July 2, 2025) through September 30, 2025, reflecting pre-revenue operational status.
• The company had not generated any revenues as of September 30, 2025, indicating it is still in the early stages of its business model.
• Financial condition is substantially dependent on the market price and liquidity of HYPE tokens, which are subject to extreme volatility and limited trading venues.

Risks

• Financial condition is substantially dependent on the market price and liquidity of HYPE tokens, which are subject to extreme volatility and limited trading venues.
• Treasury assets are concentrated in cash and HYPE tokens, meaning financial results and the carrying value of digital assets will fluctuate materially based on HYPE token price movements.
• The company depends on the continued success and adoption of the Hyperliquid protocol for the value of its treasury holdings in HYPE tokens.
• There is no assurance that additional working capital will be available when needed or on terms acceptable to the company, which could limit growth or support for the business.
• The specific impact on the company's financial condition, results of operations, cash flows, and completion of the Mergers is not determinable as of the date of these financial statements.

Future Outlook

Management expects existing resources to be sufficient to fund anticipated operations for at least one year from the date of the interim financial statements, following the significant capital raise. The company plans to use proceeds from future equity sales for general corporate purposes, including potential purchases of HYPE Tokens. The company will not generate operating revenues until after the completion of the Transaction, at the earliest.

Management Comments

• Management expects that the company's existing resources will be sufficient to enable the company to fund its anticipated level of operations through one year from the date of these interim financial statements were issued.
• The company plans to continue to pursue additional methods to obtain funding for working capital in the future, however, such funding may not be available to the company.
• To the extent we sell shares under the Purchase Agreement, we currently plan to use any proceeds therefrom for general corporate purposes, including potential purchases of HYPE Tokens.

Industry Context

This announcement positions Hyperliquid Strategies Inc. as a newly public entity with a dual focus: leveraging digital assets (HYPE tokens) and potentially monetizing legacy biotech assets from the Sonnet merger. The significant capital raise and Nasdaq listing indicate a strong entry into the public market, while the strategic advisory agreement with Rorschach Advisors LLC highlights a commitment to navigating the volatile digital asset ecosystem. The stock repurchase program, shortly after listing, suggests a proactive approach to capital management, which is notable for a company in its early operational phase post-merger. The combination of a biotech legacy and a digital asset strategy is unusual and could attract investors interested in diversified exposure to emerging technologies and traditional sectors.

Comparison to Industry Standards

• The company's strategy of holding a significant portion of its treasury in HYPE tokens, the native cryptocurrency of the Hyperliquid protocol, is comparable to other companies in the digital asset space that integrate native tokens into their balance sheets, such as MicroStrategy with Bitcoin holdings or certain DeFi protocols holding their governance tokens. However, the extreme volatility of HYPE tokens presents a higher risk profile than more established cryptocurrencies.
• The business combination with Sonnet BioTherapeutics, a biotech company, suggests a 'de-SPAC' or reverse merger type transaction, common in both biotech and emerging tech sectors for companies seeking public market access. The CVR structure for Sonnet's legacy assets is a standard mechanism in biotech M&A to provide contingent value to former shareholders based on future asset performance.
• The $1 billion equity financing facility with Chardan Capital Markets LLC is a substantial 'at-the-market' (ATM) facility, providing significant capital access, which is a common tool for growth-stage companies, particularly in biotech or technology, to fund operations and strategic initiatives without traditional underwritten offerings.
• The authorization of a $30 million stock repurchase program shortly after listing is a strong signal of management confidence, though it is unusual for a pre-revenue company that just completed a merger and secured a large financing facility. This could be compared to more mature companies using buybacks to return value to shareholders or manage dilution, but in this context, it might also be aimed at stabilizing the stock price post-listing.

Management Changes

Corporate Governance

Related Party Transactions

• Rorschach I LLC, the company's sole investor, paid $44,563 for Formation and Operating Costs on behalf of the company, recognized as 'Due to Related Parties'.
• An affiliate of the company was owed $30,023 for reimbursed expenses (legal, travel, etc.), included in 'Due to Related Party' as of September 30, 2025.
• Rorschach Advisors LLC (an affiliate) entered into an Advisor Rights Agreement and a Strategic Advisor Agreement, and was issued three Advisor Warrants and 7,761,860 Advisor Shares as part of the Business Combination Agreement. The Advisory Agreement entitles the Advisor to 5% of Common Stock and 15% warrants for future equity/equity-linked financing.

Stakeholder Impact

• **Shareholders:** Existing Sonnet shareholders received Common Stock and Contingent Value Rights (CVRs), providing a stake in the combined entity and potential future value from Sonnet's legacy assets. New investors gained exposure to a company focused on digital assets and biotech monetization. The stock repurchase program could provide price support.
• **Employees:** The approval of the 2025 Equity Incentive Plan provides a mechanism for attracting and retaining employees through stock-based awards.
• **Creditors:** The significant capital raise alleviates immediate liquidity concerns, improving the company's ability to meet its financial obligations.
• **Rorschach Advisors LLC (Affiliate):** Gained significant influence through director nomination rights (including Chairman) and potential future equity grants for advisory services, aligning their interests with the company's long-term success.

Next Steps

• Initiate a HYPE treasury strategy following the completion of the Transaction.
• Potentially direct Chardan Capital Markets LLC to purchase shares of Common Stock under the $1 billion Purchase Agreement, with proceeds used for general corporate purposes, including HYPE Token purchases.
• Monetize 'Company Legacy Assets' from the Sonnet merger within three years to trigger CVR payments.
• Implement the $30 million stock repurchase program over the next 12 months.
• Continue to pursue additional methods to obtain funding for working capital in the future.

Key Dates

Recommendation

The company has successfully completed a transformative merger and secured substantial capital, alleviating immediate going concern risks and providing a strong financial foundation. The Nasdaq listing and stock repurchase program are positive signals. However, the company is still pre-revenue, and its financial condition is highly dependent on the volatile HYPE token market. The dual focus on digital assets and legacy biotech monetization presents both opportunities and complexities. Given the early stage of operations and the inherent volatility of its core asset class, a 'hold' recommendation is appropriate for seasoned investors, allowing time to observe operational execution and the stability of its digital asset strategy before making a more definitive long-term commitment. The significant capital raise mitigates immediate downside, but the lack of operational revenue and exposure to crypto volatility warrant caution.

Keywords

Hyperliquid Strategies, Sonnet BioTherapeutics, Rorschach, Business Combination, Merger, HYPE tokens, Digital Assets, Nasdaq Listing, Equity Financing, Stock Repurchase, Biotechnology, Cryptocurrency, SEC Filing, 10-Q